Joshua Dubose
Medical · Conroe, TXNPI 1700997665
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,389 and has fallen 88.6% since, to $158 in 2025.
Across 207 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$530
- AbbVie$294
- Takeda Pharmaceuticals U.S.A., Inc.$285
- Novo Nordisk$200
- Lilly USA, LLC$193
- Pfizer$176
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,443100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,443 in reported general payments places this provider in the 75th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 163 | $201,467 |
| HumiraAdalimumab | 11 | $144,281 |
| EliquisApixaban | 49 | $52,485 |
| OzempicSemaglutide | 33 | $42,020 |
| JardianceEmpagliflozin | 29 | $36,519 |
| XareltoRivaroxaban | 18 | $20,331 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $18,828 |
| Repatha SureclickEvolocumab | 18 | $17,884 |
| JanuviaSitagliptin Phosphate | 20 | $15,621 |
| RybelsusSemaglutide | 12 | $14,836 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,611 |
| LinzessLinaclotide | 11 | $8,818 |
| Sucralfate | 20 | $4,652 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $4,463 |
| Testosterone Cypionate | 66 | $3,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $193 | $201,467163 claims |
| AbbVieHumira, Linzess, Synthroid | $294 | $154,62837 claims |
| Novo NordiskOzempic, Rybelsus | $200 | $56,85545 claims |
| PfizerEliquis | $176 | $52,48549 claims |
| Boehringer IngelheimJardiance | $94 | $36,51929 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $158 | $21,86637 claims |
| Johnson & JohnsonXarelto | $57 | $20,33118 claims |
| MerckJanuvia | $28 | $15,62120 claims |
| GSKTrelegy Ellipta | $116 | $11,61117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,490 medical providers in Texas.
Other medical in Conroe
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
- Radha BernanderKaty$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.